Biotech ETFs are near all-time highs despite overall market weakness, due to successful trials -...

|By:, SA News Editor

Biotech ETFs are near all-time highs despite overall market weakness, due to successful trials - e.g. for Vertex's (VRTX) cystic fibrosis treatment - and because some investors are betting on deals occurring. One ETF that is doing particularly well this year is iShares Nasdaq Biotech (IBB). Others include XBI, FBT and BBH.